Esmya® is well-tolerated over the long term

The safety profile of Esmya® is supported by extensive clinical studies and real-life experience. The vast majority of adverse events during intermittent and pre-operative therapy with Esmya® were mild to moderate and resolved spontaneously 7,44.

Menopausal-like adverse events decreased in frequency during intermittent therapy.
Hot flushes decreased from 5.7% to 2.8% between the first and fourth courses7.